Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 2/20 | 0.72 |
| ▸ | GALK1 | P51570 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | NAMPT | P43490 | 12/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25009697 | 0.94 | MEN1 (0.72) | RAD52GALK1MEN1KMT2AKDM4E | |
| SCHEMBL25011159 | 0.84 | RAD52 (1.00) | RAD52GALK1MEN1KMT2AKDM4E | |
| SCHEMBL20467453 | 0.84 | ALDH1A1 (0.86) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL25009208 | 0.83 | MEN1 (0.98) | RAD52GALK1MEN1KMT2AKDM4E | |
| SCHEMBL20467509 | 0.82 | ALDH1A1 (0.84) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL25009667 | 0.82 | MEN1 (0.76) | RAD52GALK1MEN1KMT2AKDM4E | |
| SCHEMBL25009221 | 0.81 | MEN1 (0.82) | RAD52GALK1MEN1KMT2AKDM4E | |
| SCHEMBL20467544 | 0.81 | ALDH1A1 (1.00) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL25010516 | 0.80 | MEN1 (0.70) | MEN1KMT2ANAMPT | |
| SCHEMBL25009416 | 0.79 | ALDH1A1 (0.76) | RAD52GALK1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041576-A1 | METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041576-A1 | METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY | NFKBIA, IKBKB, NFKB2 | RAD52 1175/4885GALK1 456/4885MEN1 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.